Clinical Trial Update: PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update indicates that the PEEL-224 study of vincristine and temozolomide for pediatric refractory or relapsed solid tumors (including neurob…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Rhabdomyosarcoma

Drugs mentioned

• Temozolomide (Temozolomide)
• Vincristine (vincristine)

Snippet

Sponsor: Theodore Laetsch | Conditions: Refractory Solid Tumors, Relapsed Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING